Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Islatravir,Doravirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MK-8591A is a combination of islatravir and Doravirine which are being investigated as non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.
Brand Name : MK-8591A
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 22, 2023
Lead Product(s) : Islatravir,Doravirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Islatravir,Doravirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Gilead Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Phase 2 study evaluating an investigational weekly oral combination treatment regimen of MK-8591 (islatravir) and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir.
Brand Name : MK-8591
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 20, 2022
Lead Product(s) : Islatravir,Doravirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Gilead Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Islatravir,Doravirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Islatravir is currently being evaluated across a variety of dosing regimens, for both the treatment of HIV-1 in combination with other antiretroviral agents and for the prevention of HIV-1 as a monotherapy.
Brand Name : MK-8591A
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 27, 2021
Lead Product(s) : Islatravir,Doravirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Islatravir,Doravirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Islatravir is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation for the treatment of people living with HIV-1 infection in combination with Doravirine.
Brand Name : MK-8591A
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 25, 2021
Lead Product(s) : Islatravir,Doravirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Islatravir,Doravirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Week 96 findings demonstrated that the combination of islatravir and doravirine maintained virologic suppression, and the findings were consistent with Week 48 results.
Brand Name : MK-8591A
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 08, 2020
Lead Product(s) : Islatravir,Doravirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Islatravir,Doravirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Merck to Present New Data from the Company’s Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020
Details : Researchers Will Present Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination with Doravirine, and Phase 1/1b Data for MK-8507, an Investigational NNRTI for the Treatment of HIV-1 Infection.
Brand Name : MK-8591A
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 01, 2020
Lead Product(s) : Islatravir,Doravirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Islatravir,Doravirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The first sub-analysis further characterized the tolerability and safety profile of islatravir in combination with doravirine (100 mg) through Week 48 across the three dose levels studied (0.25, 0.75, 2.25 mg).
Brand Name : MK-8591
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 06, 2020
Lead Product(s) : Islatravir,Doravirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Islatravir,Doravirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
Details : The data presentations also include a post-hoc analysis of weight change from the Phase 3 DRIVE-SHIFT trial evaluating the effect of switching to DELSTRIGO™ as well as an examination from the OPERA cohort of weight changes in people living with HIV.
Brand Name : MK-8591A
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 24, 2020
Lead Product(s) : Islatravir,Doravirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?